These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6702724)

  • 21. [Study of serum level of antithrombin-III antigen, antithrombin activity, and its ratio of AT-III-heparin complex formation in maintenance hemodialysis patients].
    Yoshida K; Saka M; Kaneko Y; Kubota K; Hirao Y; Okajima E; Ishida M; Kihouin K; Motomiya Y
    Nihon Jinzo Gakkai Shi; 1989 Nov; 31(11):1171-7. PubMed ID: 2625740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
    Herren T; Straub PW; Haeberli A
    Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anticoagulant effect of heparin + antithrombin III using purified fibrinogen as substrate.
    Andersen P; Godal HC
    Haemostasis; 1977; 6(6):329-38. PubMed ID: 611046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unsuitability of laser nephelometer in the evaluation of factor VIII antigen.
    Ruzza G; Viero M; Lazzaro AR; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):269-75. PubMed ID: 2475407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heparin cofactor II assay. Elimination of heparin and antithrombin-III effects.
    Nakhleh R; Vogt JM; Edson JR
    Am J Clin Pathol; 1988 Mar; 89(3):353-8. PubMed ID: 3348170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
    Tripodi A; Krachmalnicoff A; Mannucci PM
    Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombin III Alger: a new homozygous AT III variant.
    Fischer AM; Cornu P; Sternberg C; Mériane F; Dautzenberg MD; Chafa O; Beguin S; Desnos M
    Thromb Haemost; 1986 Apr; 55(2):218-21. PubMed ID: 3715788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity.
    Béguin S; Kessels H; Dol F; Hemker HC
    Thromb Haemost; 1992 Aug; 68(2):136-42. PubMed ID: 1412157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin-antithrombin III binding. In vitro and in vivo studies.
    Chan V; Chan TK
    Haemostasis; 1979; 8(6):373-89. PubMed ID: 511016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ANTITHROMBIN ACTIVITY (HEPARIN CO-FACTOR) IN PLASMA AFTER MAJOR SURGERY IN HEPARINIZED PATIENTS.
    OLSSON P; VON FRANCKEN ; NORDSTROEM S
    Acta Chir Scand; 1964 Jun; 127():578-83. PubMed ID: 14175132
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhibition of urokinase by complex formation with human antithrombin III in absence and presence of heparin.
    Clemmensen I
    Thromb Haemost; 1978 Jun; 39(3):616-23. PubMed ID: 705690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of interference by heparin cofactor II in the DuPont aca antithrombin-III assay.
    Hortin GL; Tollefsen DM; Santoro SA
    Am J Clin Pathol; 1988 Apr; 89(4):515-7. PubMed ID: 3354504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Progressively acting antithrombins and plasma heparin resistance in ischemic heart disease].
    Barkagan ZS; Bishevskiĭ KM; Vidiakov GE; Kungurov IA
    Kardiologiia; 1981 Aug; 21(8):31-5. PubMed ID: 7289382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetic analysis of the heparin-enhanced plasmin--antithrombin III reaction. Apparent catalytic role of heparin.
    Machovich R; Bauer PI; Arányi P; Kecskés E; Büki KG; Horváth I
    Biochem J; 1981 Dec; 199(3):521-6. PubMed ID: 6462134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity of the "classical" antithrombin III deficiency.
    Sas G; Petö I; Bánhegyi D; Blaskó G; Domján G
    Thromb Haemost; 1980 Jun; 43(2):133-6. PubMed ID: 7455972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STUDIES ON THROMBIN INACTIVATION IN NORMAL PLASMA, SERUM AND PLASMA FRACTIONS, AND ITS RELATION TO HEPARIN.
    BLOMBAECK B; BLOMBAECK M; OLSSON P
    Thromb Diath Haemorrh; 1963 Jul; 143():368-86. PubMed ID: 14081260
    [No Abstract]   [Full Text] [Related]  

  • 37. Identification of a new SERPINC1 mutation in a Kazak family that alters the heparin binding capacity of antithrombin.
    Zheng H; Ma HP; Xu WF; Zhang YQ; Wu JJ; Wang J
    Thromb Res; 2014 Dec; 134(6):1344-9. PubMed ID: 25312341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and function probing of an antithrombin IIIβ conformation-specific antibody.
    Jin Y; Yegneswaran S; Gu JM; Gritzan U; Schönfeld DL; Paz P; Patel C; Dittmer F; Strerath M; Bringmann P; Kauser K; Myles T; Murphy JE; Hermiston TW
    J Thromb Haemost; 2016 Feb; 14(2):356-65. PubMed ID: 26581031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
    Hoylaerts M; Holmer E; de Mol M; Collen D
    Thromb Haemost; 1983 Apr; 49(2):109-15. PubMed ID: 6868006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Abnormal antithrombin III: abnormalities of heparin or protease binding domain].
    Sakuragawa N; Niiya K; Takahashi K; Hayashi T; Oguma Y; Saitoh S
    Rinsho Byori; 1993 May; 41(5):492-505. PubMed ID: 8350512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.